Test kit, composition and a method of measuring vitamin D and its metabolites in a sample of bodily fluid from a subject, which sample contains vitamin D binding protein (DBP), comprising the steps of contacting said sample with megalin and/or a soluble fragment thereof under binding conditions to form a ternary complex containing DBP, a vitamin D metabolite and megalin or a fragment thereof; determining the amount of DBP bound by megalin; and relating the amount of megalin-bound DBP to the effective status of vitamin D in the circulation of said subject.

p80 is a cancer/proliferation-related protein identified as being present in bodily fluids or tissues (including blood) of humans or animals afflicted with pre-malignant, malignant cells/tissues or proliferative conditions. The methods of the present disclosure provide a new diagnostic marker for screening of cancers and proliferative conditions. The present application discloses screening, diagnosis, and monitoring of these conditions by novel Point-of-Service tests. The addition of p80-bound tubulin testing is also claimed. Additionally, the present application discloses targeted treatment of cancer and proliferative conditions utilizing p80 binding agents, via a variety of delivery vehicles such as nanoparticles. The claims apply to application in domestic or wild animals.

The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.

Systems are described, based on a primary binding compound and a secondary binding compound used in combination with a support to detect a target in a sample. The systems includes at least one support structure, at least one small primary support portion containing at least one molecule covalently bound to a visual colloidal marker, a plurality of secondary support portions comprising secondary binding compounds that are covalently bound to the support portions and chemically active, at least one pH litmus indicator, at least one pH strip, a buffer for lateral flow on the porous membrane support that allows preservation and activity of binding compounds.

Provided herein are compositions comprising a double-stranded RNA (dsRNA) binding domains linked to components of a complementation system. Upon binding of a pair of dsRNA binding domains to a dsRNA, a detectable complex of the complementation components is formed, and the dsRNA can be detected/quantified.

Disclosures herein are directed to antibodies and epitope binding agents that specifically bind to RoxP of Cutebacterium sp. and compositions thereof for use in clinical and non-clinical applications.

Detector systems are described, based on a primary binding compound and a secondary binding compound used in combination with a support to detect a target in a sample. The detection systems include a liquid medium hosting a first binding compound specific to a target, the first binding compound comprising a label; and a solid medium hosting a second binding compound specific to the target, the second binding compound being different from and non-competitive with respect to the first binding compound.

A kit for detecting an antigen from which false positive signals are removed is provided. The kit includes a substrate; a capture antibody attachable onto the substrate and having a capture strand labeled with a fluorescent material; a detection antibody having a detection strand labeled with a fluorescent material and complementary to some or all of a base sequence of the capture strand; and a blocking strand having a base sequence capable of complementary binding to the capture strand or the detection strand to prevent the detection strand and the capture strand from complementary binding to each other.

The present disclosure relates to a chemiluminescent substrate solution and a chemiluminescence detection method. The chemiluminescent substrate solution includes a chemiluminescent substrate, a fluorescein, and a water-soluble polymeric quaternary ammonium salt, wherein the chemiluminescent substrate is selected from chlorinated dioxetane compounds with a spiroadamantane substituent. The chemiluminescent substrate solution has a wider linear detection range.

An object of the present invention is to provide a monoclonal antibody capable of specifically detecting and capturing HRG in a test sample, a set (combination) thereof, and a method for measuring HRG using the same. As a result of intensive studies, the present inventors have found an antibody capable of detecting and capturing HRG in a test sample with good sensitivity and specificity, a set thereof, and a method for measuring HRG using the same, thereby completing the present invention.